KR20240016344A - 유방암의 치료 방법 - Google Patents

유방암의 치료 방법 Download PDF

Info

Publication number
KR20240016344A
KR20240016344A KR1020237045312A KR20237045312A KR20240016344A KR 20240016344 A KR20240016344 A KR 20240016344A KR 1020237045312 A KR1020237045312 A KR 1020237045312A KR 20237045312 A KR20237045312 A KR 20237045312A KR 20240016344 A KR20240016344 A KR 20240016344A
Authority
KR
South Korea
Prior art keywords
olaparib
breast cancer
patients
treatment
free survival
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237045312A
Other languages
English (en)
Korean (ko)
Inventor
아니트라 필딩
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20240016344A publication Critical patent/KR20240016344A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
KR1020237045312A 2021-06-02 2022-05-31 유방암의 치료 방법 Withdrawn KR20240016344A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163195795P 2021-06-02 2021-06-02
US63/195,795 2021-06-02
PCT/EP2022/064697 WO2022253800A1 (en) 2021-06-02 2022-05-31 Methods of treating breast cancer

Publications (1)

Publication Number Publication Date
KR20240016344A true KR20240016344A (ko) 2024-02-06

Family

ID=82117716

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237045312A Withdrawn KR20240016344A (ko) 2021-06-02 2022-05-31 유방암의 치료 방법

Country Status (12)

Country Link
US (1) US20240269135A1 (https=)
EP (1) EP4346828A1 (https=)
JP (1) JP2024520142A (https=)
KR (1) KR20240016344A (https=)
CN (1) CN118139624A (https=)
AU (1) AU2022286616A1 (https=)
BR (1) BR112023025003A2 (https=)
CA (1) CA3220751A1 (https=)
CL (1) CL2023003533A1 (https=)
IL (1) IL308684A (https=)
MX (1) MX2023014420A (https=)
WO (1) WO2022253800A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu

Also Published As

Publication number Publication date
JP2024520142A (ja) 2024-05-21
CA3220751A1 (en) 2022-12-08
MX2023014420A (es) 2024-04-23
CN118139624A (zh) 2024-06-04
WO2022253800A1 (en) 2022-12-08
US20240269135A1 (en) 2024-08-15
BR112023025003A2 (pt) 2024-02-20
AU2022286616A1 (en) 2024-01-18
IL308684A (en) 2024-01-01
EP4346828A1 (en) 2024-04-10
CL2023003533A1 (es) 2024-06-28

Similar Documents

Publication Publication Date Title
Dickler et al. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
Ehmann et al. Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers
Edwards et al. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation
Guo et al. Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study
Eule et al. Outcomes of second-line therapies in patients with metastatic de novo and treatment-emergent neuroendocrine prostate cancer: a multi-institutional study
Desai et al. Patterns of relapse in stage I–II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy
Zhang et al. A staged procedure in the treatment of primary lacrimal sac epithelial malignancy: a retrospective cases analysis
Bimbatti et al. Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma
Lu et al. Examining the impact of tislelizumab added to chemotherapy on health-related quality-of-life outcomes in previously untreated patients with nonsquamous non–small cell Lung Cancer
Kim et al. Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
US20240180893A1 (en) Methods of treatment of breast cancer
Yu et al. Post-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity
van Nijnatten et al. Implementation of model-informed precision dosing for tamoxifen therapy in patients with breast cancer: A prospective intervention study
Greto et al. Patterns of care and survival in elderly patients with locally advanced soft tissue sarcoma
Takahashi et al. Long-term efficacy of immune checkpoint inhibitor for squamous cell carcinoma lesion transformed from EGFR-mutated adenocarcinoma after osimertinib treatment: a case report
KR20240016344A (ko) 유방암의 치료 방법
EP4493185A1 (en) Treatment of breast cancer with amcenestrant
Cui et al. Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study
Pujari et al. Outcomes of de novo oligometastatic breast cancer treated with surgery of primary and metastasis directed radiotherapy
Team Pertuzumab (Perjeta)
Grigorescu et al. Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced non-small cell lung cancer patients
Raab et al. Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCC
Mu et al. Efficacy and safety of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: A systematic review and meta-analysis
Guo et al. Long‑term survival of a patient with advanced lung cancer treated with targeted therapy and anti‑PD‑1 immunotherapy as multi‑line therapy: A case report
Maltoni et al. Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer: A case report

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202